DCTH - Delcath Systems Inc logo

DCTH

Delcath Systems Inc

Delcath Systems develops treatment solutions for primary and metastatic liver cancers, focusing on its HEPZATO KIT for administering high-dose chemotherapy directly to the liver. The company markets the CHEMOSAT system in Europe for similar applications.

⚕️ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 20 years ago $3,422today

Score Overview

1 Year
Score
Net Growth-80.30%
Net TrendShrank
Net Income Consistency
Rev Growth11.95%
Rev TrendGrew
Revenue Consistency
5 Years
Score5.6
Net Growth102.07%
Net Trend40%
Net Income Consistency
Rev Growth26x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth102.77%
Net Trend38%
Net Income Consistency
Rev Growth28x
Rev Trend63%
Revenue Consistency

See the full market ranking →

Delcath Systems Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 1M to $ 85M and net income went from -$ 24M to $ 2M. Revenue increased in 3 of those 5 years; net income in 2.

Delcath Systems Inc currently holds a 5-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 17.11
1 Year2025-08-12
$ 10.8857.26%
5 Years2021-08-12
$ 9.3582.99%
10 Years2016-08-12
$ 3.92336.48%
20 Years2006-08-11
$ 5.00242.20%
All Time2018-05-29
$ 2.1K-99.19%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 95M$ 532K$ 95M
2025$ 85M$ 2M$ 91M
2024$ 37M-$ 26M$ 53M
2023$ 2M-$ 47M$ 32M
2022$ 2M-$ 36M$ 7M
2021$ 3M-$ 25M$ 22M
2020$ 1M-$ 24M$ 28M
2019$ 1M-$ 8M$ 10M
IPO2018$ 3M-$ 19M$ 2M

Explore beyond DCTH

You're looking at Delcath Systems Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies